Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
Go back to Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments| Gilead Sciences (NASDAQ: GILD) | Delayed: 125.05 +0.18 (0.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $124.87 | 52 Week High | $108.63 | |||
| Open | $126.63 | 52 Week Low | $71.39 | |||
| Day High | $126.63 | P/E | 69.09 | |||
| Day Low | $124.44 | EPS | $1.81 | |||
| Volume | 7,979,947 | |||||
| NOVEN PHARMACEUTIC (NASDAQ: NOVN) | Delayed: 0.09 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.09 | 52 Week High | $23.79 | |||
| Open | $10.12 | 52 Week Low | $13.73 | |||
| Day High | $0.09 | P/E | 0.09 | |||
| Day Low | $0.09 | EPS | $1.05 | |||
| Volume | 1,574,031 | |||||
